Literature DB >> 22150168

A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy.

Greetta Joensuu, Timo Joensuu, Nina Nupponen, Mirja Ruutu, Juhani Collan, Sari Pesonen, Akseli Hemminki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22150168     DOI： 10.3109/0284186X.2011.617387

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  3 in total

1.  Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.

Authors:  Andliena Tahiri; Kathrine Røe; Anne H Ree; Rik de Wijn; Karianne Risberg; Christian Busch; Per E Lønning; Vessela Kristensen; Jürgen Geisler
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

2.  Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.

Authors:  Laura Mercatali; Federico La Manna; Giacomo Miserocchi; Chiara Liverani; Alessandro De Vita; Chiara Spadazzi; Alberto Bongiovanni; Federica Recine; Dino Amadori; Martina Ghetti; Toni Ibrahim
Journal:  Int J Mol Sci       Date:  2017-07-29       Impact factor: 5.923

3.  The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.

Authors:  C J Paller; D Olatoye; S Xie; X Zhou; S R Denmeade; M A Eisenberger; E S Antonarakis; M A Carducci; G L Rosner
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-10-08       Impact factor: 5.554
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.